Linda Sutton, MD
Medical Oncology · Roxboro, NCNPI 1366409575
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,922 of the $8,003 with a category attached, or 74.0%. 16 manufacturers reported payments, led by Pfizer at 56.5% of the total. Reporting peaked in 2023 at $5,860 and has fallen 97.4% since, to $154 in 2025.
Across 40 payments — averaging $200.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$5K
- AstraZeneca$2K
- Gilead$1K
- Johnson & Johnson$206
- Merck$109
- Beone Medicines USA, Inc.$49
- plus $231 from 10 others
Across 5 payments — averaging $5300.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$25K
- Pfizer$2K
What the payments were for
- Consulting fees$1,28016%
- Speaking & faculty fees$5,92274%
- Food & beverage$6919%
- Education$1111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 5 | $4,522 |
| AstraZeneca | 5 | $1,579 |
| Gilead(2 entities) | 3 | $1,306 |
| Johnson & Johnson(2 entities) | 8 | $206 |
| Merck | 5 | $109 |
| Beone Medicines USA, Inc. | 2 | $49 |
| Sobi, Inc | 2 | $37 |
| Genmab U.S., Inc. | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Sanofi | 2 | $27 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Eisai Inc. | 1 | $20 |
| Spectrum Pharmaceuticals Inc. | 1 | $19 |
| Bristol Myers Squibb | 1 | $17 |
| EMD Serono, Inc. | 1 | $16 |
| Array Biopharma Inc | 1 | $13 |
How this compares
$8,003 in reported general payments places this provider in the 70th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exemestane | 14 | $1,865 |
| Letrozole | 63 | $902 |
| Prochlorperazine Maleate | 21 | $351 |
| Tamoxifen Citrate | 11 | $250 |
| Ondansetron Hcl | 26 | $195 |
| Anastrozole | 13 | $143 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 11 | $92 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Roxboro
- Thomas LeblancDurham$1.7M
- David RizzieriCharlotte$714K
- Raghava InduruAlbemarle$625K
- Nilanjan GhoshCharlotte$510K
- Mohamed SalemCharlotte$396K
- Andrew ArmstrongDurham$377K
- John StricklerDurham$319K
- Neal ReadyDurham$309K
- Thomas StinchcombeChapel Hill$281K
- Steven SorscherWinston Salem$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.